• Journal of IKEEE
• /
• v.25 no.1
• /
• pp.174-179
• /
• 2021

An Edwards curve cryptography (EdCC) core supporting point scalar multiplication (PSM) on Edwards curves of Edwards25519 and Edwards448 was designed. For area-efficient implementation, finite field multiplier based on word-based Montgomery multiplication algorithm was designed, and the extended twisted Edwards coordinates system was adopted to implement point operations without division operation. As a result of synthesizing the EdCC core with 100 MHz clock, it was implemented with 24,073 equivalent gates and 11 kbits RAM, and the maximum operating frequency was estimated to be 285 MHz. The evaluation results show that the EdCC core can compute 299 and 66 PSMs per second on Edwards25519 and Edwards448 curves, respectively. Compared to the ECC core with similar structure, the number of clock cycles required for 256-bit PSM was reduced by about 60%, resulting in 7.3 times improvement in computational performance.

• Journal of the Korea Institute of Information Security & Cryptology
• /
• v.31 no.1
• /
• pp.19-30
• /
• 2021

In this paper, when SIDH is instantiated using only 3- and 5-isogeny, we demonstrate which curve is more efficient among the Montgomery, Edwards, and Huff curves. To this end, we present the computational cost of the building blocks of SIDH on Montgomery, Edwards, and Huff curves. We also present the prime we used and parameter settings for implementation. The result of our work shows that the performance of SIDH on Montgomery and Huff curves is almost the same and they are 0.8% faster than Edwards curves. With the possibility of using isogeny of degree other than 3 and 4, the performance of 5-isogeny became even more essential. In this regard, this paper can provide guidelines on the selection of the form of elliptic curves for implementation.

• Journal of Chest Surgery
• /
• v.19 no.1
• /
• pp.35-42
• /
• 1986

Prevention of thrombombolism after rosthetic cardiac valve replacement is essential for the patients. About 90% of patients are free of major and minor thromboembolic complications 5 year after replacement of cardiac valves with prosthetic devices when they are under control of anticoagulant therapy. Ticlopidine is a drug that alter platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP and increases the production of prostaglandin $D_{2}$. Aspirin in small doses inhibits platelet synthesis of prostaglandins by irreversibly blocking the enzyme cyclo-oxygenase. Platelet secretion and aggregation are impaired with Ticlopidine and Aspirin. the thromboembolic event sof 54 patient s who were treated with Ticlopidine and Aspirin after cardiac valve replacement were evaluated and compared with that of 79 patients who were treated with Wafarin and Aspirin after the same type of operation. The follow-up period ranged from 4 to 110 months (mean of 48 months). there were 11 major thromboembolic episodes including three deaths in the warfarin goup during mean follow-up period of 56 months. two cases of CVA and one hemoarthrosis were noted due to overdose of Warfarin. Inticlopidine group, there was only one fatal thromboembolic epdisode three month after mitral valve replacement during mean follow-up period of 18 months. Two episodes of hypermenorrhea resulting anemia ere noted in the ticlopidine group. We measured the parameters of platelet function in aggreagation curve of platelet with platelet aggregometer (chrono-log Aggregometer, Model No. 430) Aggregation test was performed with three final concentrations of epinephrine in 10 uM/L, ADP in 5uM/L. 28 patients with prosthetic cardiac valves and 35 healthy volunteers were subgrouped as follows to analyze the effect of antithrombotic drugs used. Group I ; 11 patients treated with 250-500 mg of ticlopidine and 0.5gm of Aspirin as a daily single dose after cardiac valve replacement (14 St. Jude Medical and 1 Carpentier-Edwards, 9 patients with atrial fibrillation among them) Group II ; 10 patients treated with 3-5 mg of Warfarin and 0.75 gm of Aspirin daily to prolong prothrombin time around 20 seconds for more than 6 months and single Aspirin dose was maintained afterward as a life-long regimes(3 St. Jude Medical, 1 Hall-Kaster and 7 Carpentier-Edwards valve, 9 patients in atrial fibrilation). Group III ; 7 patients who quit anticoagulant treatment (Warfarin + Aspirin) 6-12 months after the regime as group II (3 St. Jude Medical. 1 bjork-Shiley, 1 Hall-Kaster, 3 Carpentier-Edwards valve, 2 of them are with atrial fibrillation). Group IV ; 35 healthy vounteers (28 males and 7 females). The following results were obtained. 1. The mean maximal platelet aggregability in Group I induced by 10uM/L epinephrine was 15.6%, and 17.5 and 18.7% in BM in proportion to the induction by 5 and 10 uM/L ADP. 2. The mean maximal platelet aggregability in Group II induced by 10uM/L epinephrine was 16.5%, and 27.4 and 44.7% in BM in proportion to the induction by 5 and 10uM/L ADP. 3. The mean maximal platelet aggregability in group III induced by 10uM/L epinephrine was 65%, and 56.5 and 51.8% in BM in proportion to the induction by 5 and 10 uM/L ADP. 4. The mean maximal platelet aggregability in the normal subjects induced by 10 uM/L epinephrine was 64%, and 65 and 69% in Bm inproportion to the induction by 5 and 10 uM/L ADP. 5. Reversible change of platelet aggregation curve induced by 5 and 10uM/L was noted all of the patients in Group I. conclusion : Ticlopidine is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP, and increases the production of prostaglandin $D_{2}$. Ticlopidine and Aspirin produced a significant inhibition of platelet in the presence of ADP and epinephrine in our study. Acccording to our brief experience, 250 mg of ticlopidine and low dose of Aspirin resulted synergistic superior effect to each drug alone in prevention of thromboembolism after prosthetic cardiac valve replacement.

• The Korean Journal of Rheology
• /
• v.1 no.1
• /
• pp.54-62
• /
• 1989

준희박과 농축용액에서 약간의 유연성을 갖는 강성막대형 고분자의 회전확산계수와 zero shear rate 점도를 예측하기 위해 한정된 강성 사슬모델이 제시되었다. 본 연구에서는 이제시된 모델을 분자량 분포를 갖는 다분산계로 확장시켰다. 분자들의 분자량 분포 (MW/Mn) 와 분포 함수를 알수 없기 때문에 해당분자에 가장 적당한 분자량 분포와 함수를 취하였다. 만약 이것들을 알고 있다면 제시된 모델로 회전확산계수와 zero shear rate 점도 등과 같은 인자들을예측할수 있었다. 단분산계의 경우와 같이 다분산계에서도 회전확산계수 의 평균분자 윤곽길이 의존도는 L-7 에 비례하는 것으로 나타났다. Doi와 Edwards 의 튜브 모델에 의한 L-9 과 다른 이유는 분자들의 거동을 관찰하기 위해 임의로 선정된 하나의 막 대형 고분자운동을 제약하는 정도가 심하지 않았으며 따라서 제약 완화시간도 훨씬 짧았기 때문이다. 더구나 점도와 회전 확산계수와 단분산계에서는 정성적으로 일치한데 제약 완화 시간도 훨씬 짧았기 때문이다. 더구나 점도와 회전적인 일치를 나타내었다. 이 모델로 기준 으로 하여 분자들의 길이와 종류에 관계없이 하나의 master curve를 그릴수 있었다.